The gateway to everything entrepreneurial at Cornell University

Cornell Venture Capitalists

Pearl Chin

MBA '00

Managing Director
Seraphima Ventures (New York City, NY)

Biography

Dr. Chin specializes in advising on nanotechnology investment opportunities. Dr. Chin has extensive experience in strategy and marketing consulting, management consulting, operations, sales and marketing, and customer service, in diverse industries from small to large companies.

Dr. Chin contributed to NASA's Grand Challenge Workshop 2004 for Nanotechnology and NASA's Exploration Vision her views of the opportunities and needs for research and development in nanotechnology and what can be accomplished in the next 10 years.

She was a management consultant with Pittiglio Rabin Todd & McGrath (PRTM)'s Chemicals, Engineered Materials and Packaged Goods group optimizing Supply Chain Management and Change Management operations (Business Process Re-engineering) for technical companies. Before that, she was an Applications Consultant under Sales and Marketing and headed domestic Customer Support for TA Instruments, Inc. (spinout from DuPont as DuPont Instruments) when TAI was number one in Customer Support in their industry. She was Managing Director of the US offices and co-Managing Director of the London offices of Cientifica, a global nanotechnology consultancy providing business information, marketing analyses and business strategy consulting to Fortune 500 companies and investment firms. She has also worked with Lederle Laboratories (formerly of American Cyanamid Company now known as part of Wyeth) and also with the Colgate Palmolive Company.

Dr. Chin also has extensive technology research expertise. She was a Guest Scientist collaborating with the National Institute of Standards & Technology (NIST) Polymer Division's Electronic Materials Group under the US Department of Commerce. She received a NIST Fellowship for graduate study and a Henry Enders Graduate Study Scholarship from The Cooper Union. Her PhD research focused on characterizing nanoscale polymer films for electronics packaging applications and studying fundamental adhesion phenomena. She also studied nanoscale interfacial phenomena and effects on mechanical properties of graphite fiber reinforced epoxy composites systems for military, automotive, sporting goods and other high performance applications. To round herself out, she was an alternate finalist for a Congressional Fellowship with the Materials Research Society.

She is actively sought out to speak about the business of investing in nanotechnology and has written widely on investing, business, management, strategy and social issues in nanotechnology. Her articles have appeared in the Nanotechnoloy Law & Business Journal, European based Alt Assets (private equity research), Cornell Enterprise Magazine, the U.S. based Nanotechnology Now and Netherlands based Nano-Tsunami sites as well as for Tech Valley Times in Upstate New York, a designated economic development region focusing on hi-tech development.

Dr. Chin also spends time advising small businesses in the downtown Lower East Side Manhattan area with the Chinatown-Lower East Side Business Outreach Center as part of her economic development and community service activities after 9-11.

Dr. Chin was born and raised in New York City. She enjoys gourmet food and cooking, travel, reading, philosophy, dancing and seeks to become an oenophile. Dr. Chin speaks Cantonese, has working knowledge of French, Japanese and Mandarin and dabbles in Farsi (Persian).

Education

Dr. Pearl Chin has an MBA (Commencement Marshall) from Cornell University's Johnson Graduate School of Management (JGSM), a PhD in Materials Science and Engineering from University of Delaware's Center for Composite Materials and BE in Chemical Engineering from The Cooper Union in New York City. Dr. Chin also has her Series 7.

Board Affiliations

Dr. Chin is the President of the Foresight Nanotech Institute which was founded in 1986 by Dr. K. Eric Drexler and which is the leading nanotechnology think tank in the U.S. She is on the Board of Directors of Biophage Pharma, a Canadian biotech company focusing on phage therapies. She also works with the Institute of Bioengineering and Nanotechnology (IBN) in Singapore.